metformin has been researched along with Fetal Macrosomia in 23 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Fetal Macrosomia: A condition of fetal overgrowth leading to a large-for-gestational-age FETUS. It is defined as BIRTH WEIGHT greater than 4,000 grams or above the 90th percentile for population and sex-specific growth curves. It is commonly seen in GESTATIONAL DIABETES; PROLONGED PREGNANCY; and pregnancies complicated by pre-existing diabetes mellitus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For pregnant women who are overweight or obese, metformin given in addition to dietary and lifestyle advice initiated at 10-20 weeks' gestation does not improve pregnancy and birth outcomes." | 9.30 | Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. ( Dekker, G; Deussen, AR; Dodd, JM; Grivell, RM; Hague, W; Louise, J; McPhee, AJ, 2019) |
| "A pilot randomized, controlled trial was conducted of metformin versus insulin for the treatment of T2DM during pregnancy." | 9.20 | A pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy. ( Blackwell, SC; Gowen, R; Hutchinson, M; Pedroza, C; Ramin, S; Refuerzo, JS, 2015) |
| "Prospectively assess whether metformin/diet pre-conception and throughout pregnancy would safely reduce first trimester miscarriage and improve pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 9.17 | Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Khan, Z; Padda, J; Pranikoff, J; Wang, P, 2013) |
| "To evaluate the impact of preemptive metformin on the level of glycosylated hemoglobin (HbA1c) at 36 weeks of pregnancy in women with gestational diabetes mellitus controlled by diet change (GDMA1)." | 5.51 | Metformin in gestational diabetes mellitus: A double-blind placebo-controlled randomized trial. ( Hong, JGS; Omar, SZ; Saaid, R; Tan, PC; Tew, MP, 2022) |
| "Metformin was then administered." | 5.32 | Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy. ( Imamura, M; Mori, M; Nagai, T, 2003) |
| "For pregnant women who are overweight or obese, metformin given in addition to dietary and lifestyle advice initiated at 10-20 weeks' gestation does not improve pregnancy and birth outcomes." | 5.30 | Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. ( Dekker, G; Deussen, AR; Dodd, JM; Grivell, RM; Hague, W; Louise, J; McPhee, AJ, 2019) |
| "This is a randomized double-blind multi-center clinical trial of insulin plus metformin versus insulin plus placebo for the treatment of type 2 diabetes complicating pregnancy." | 5.27 | Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study. ( Berry, DC; Boggess, K; de Los Angeles Abreu, M; Dorman, KF; Ivins, AR; Thomas, SD; Young, L, 2018) |
| "Among women without diabetes who had a BMI of more than 35, the antenatal administration of metformin reduced maternal weight gain but not neonatal birth weight." | 5.22 | Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. ( Akolekar, R; Balani, J; Hyer, S; Kotecha, R; Nicolaides, KH; Pastides, A; Shehata, H; Syngelaki, A, 2016) |
| "A pilot randomized, controlled trial was conducted of metformin versus insulin for the treatment of T2DM during pregnancy." | 5.20 | A pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy. ( Blackwell, SC; Gowen, R; Hutchinson, M; Pedroza, C; Ramin, S; Refuerzo, JS, 2015) |
| "Prospectively assess whether metformin/diet pre-conception and throughout pregnancy would safely reduce first trimester miscarriage and improve pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 5.17 | Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Khan, Z; Padda, J; Pranikoff, J; Wang, P, 2013) |
| " The neonates of metformin group had less rate of birth weight centile >90 than insulin group (RR: 0." | 5.16 | Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial. ( Akbari, S; Alavi, A; Amjadi, N; Moosavi, S; Niromanesh, S; Sharbaf, FR, 2012) |
| "Our study concluded that metformin is fastest in glucose control, with a more favorable pregnancy outcomes-would be a better option, but its rate of glucose control is the lowest." | 4.95 | Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus: An updated PRISMA-compliant network meta-analysis. ( Liang, HL; Ma, SJ; Tan, HZ; Xiao, YN, 2017) |
| " Metformin was tolerated throughout the pregnancy by 90% of the women in the metformin+lifestyle advice group." | 3.78 | Introduction of metformin for gestational diabetes mellitus in clinical practice: Has it had an impact? ( Bustani, R; Farrell, T; Gandhi, P; Madhuvrata, P, 2012) |
| "In a south Indian population with gestational diabetes, metformin was associated with better neonatal outcomes than glibenclamide." | 2.80 | Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide--a randomised controlled trial. ( Abraham, A; Antonisamy, B; Beck, M; Benjamin, SJ; George, A; Jana, AK; Mathews, JE; Sam, D; Thomas, N, 2015) |
| "Metformin has no significant effect on birthweight percentile in obese pregnant women." | 2.80 | Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. ( Chiswick, C; Denison, F; Drake, AJ; Forbes, S; Lashen, H; Murray, G; Newby, DE; Norman, JE; Quenby, S; Reynolds, RM; Rodriguez, A; Walker, BR; Weeks, A; Whyte, S; Wray, S, 2015) |
| "At short term, in women with gestational diabetes requiring drug treatment, glibenclamide is clearly inferior to both insulin and metformin, while metformin (plus insulin when required) performs slightly better than insulin." | 2.52 | Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. ( Balsells, M; Corcoy, R; García-Patterson, A; Gich, I; Roqué, M; Solà, I, 2015) |
| "Metformin has been increasingly popular in recent years." | 1.48 | Longer-term outcomes in offspring of GDM mothers treated with metformin versus insulin. ( Chen, C; Li, X; Zhen, XM, 2018) |
| "Metformin was then administered." | 1.32 | Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy. ( Imamura, M; Mori, M; Nagai, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 20 (86.96) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Tew, MP | 1 |
| Tan, PC | 1 |
| Saaid, R | 1 |
| Hong, JGS | 1 |
| Omar, SZ | 1 |
| Liang, HL | 1 |
| Ma, SJ | 1 |
| Xiao, YN | 1 |
| Tan, HZ | 1 |
| Aiken, CEM | 1 |
| Hone, L | 1 |
| Murphy, HR | 1 |
| Meek, CL | 1 |
| Zhen, XM | 1 |
| Li, X | 1 |
| Chen, C | 1 |
| Dodd, JM | 1 |
| Louise, J | 1 |
| Deussen, AR | 1 |
| Grivell, RM | 1 |
| Dekker, G | 1 |
| McPhee, AJ | 1 |
| Hague, W | 1 |
| Berry, DC | 1 |
| Thomas, SD | 1 |
| Dorman, KF | 1 |
| Ivins, AR | 1 |
| de Los Angeles Abreu, M | 1 |
| Young, L | 1 |
| Boggess, K | 1 |
| Bashir, M | 1 |
| Dabbous, Z | 1 |
| Baagar, K | 1 |
| Elkhatib, F | 1 |
| Ibrahim, A | 1 |
| Brich, SA | 1 |
| Abdel-Rahman, ME | 1 |
| Konje, JC | 1 |
| Abou-Samra, AB | 1 |
| Egan, AM | 1 |
| Brassill, MJ | 1 |
| Brosnan, E | 1 |
| Carmody, L | 1 |
| Clarke, H | 1 |
| Coogan Kelly, C | 1 |
| Culliney, L | 1 |
| Durkan, M | 1 |
| Fenlon, M | 1 |
| Ferry, P | 1 |
| Hanlon, G | 1 |
| Higgins, T | 1 |
| Hoashi, S | 1 |
| Khamis, A | 1 |
| Kinsley, B | 1 |
| Kinsley, T | 1 |
| Kirwan, B | 1 |
| Liew, A | 1 |
| McGurk, C | 1 |
| McHugh, C | 1 |
| Murphy, MS | 1 |
| Murphy, P | 1 |
| O'Halloran, D | 1 |
| O'Mahony, L | 1 |
| O'Sullivan, E | 1 |
| Nolan, M | 1 |
| Peter, M | 1 |
| Roberts, G | 1 |
| Smyth, A | 1 |
| Todd, M | 1 |
| Tuthill, A | 1 |
| Wan Mahmood, WA | 1 |
| Yousif, O | 1 |
| P Dunne, F | 1 |
| Pascual-Morena, C | 1 |
| Martínez-Vizcaíno, V | 1 |
| Álvarez-Bueno, C | 1 |
| Pozuelo-Carrascosa, DP | 1 |
| Notario-Pacheco, B | 1 |
| Saz-Lara, A | 1 |
| Fernández-Rodriguez, R | 1 |
| Cavero-Redondo, I | 1 |
| Refuerzo, JS | 1 |
| Gowen, R | 1 |
| Pedroza, C | 1 |
| Hutchinson, M | 1 |
| Blackwell, SC | 1 |
| Ramin, S | 1 |
| Balsells, M | 1 |
| García-Patterson, A | 1 |
| Solà, I | 1 |
| Roqué, M | 1 |
| Gich, I | 1 |
| Corcoy, R | 1 |
| George, A | 1 |
| Mathews, JE | 1 |
| Sam, D | 1 |
| Beck, M | 1 |
| Benjamin, SJ | 1 |
| Abraham, A | 1 |
| Antonisamy, B | 1 |
| Jana, AK | 1 |
| Thomas, N | 1 |
| Refuerzo, J | 1 |
| Chiswick, C | 1 |
| Reynolds, RM | 1 |
| Denison, F | 1 |
| Drake, AJ | 1 |
| Forbes, S | 1 |
| Newby, DE | 1 |
| Walker, BR | 1 |
| Quenby, S | 1 |
| Wray, S | 1 |
| Weeks, A | 1 |
| Lashen, H | 1 |
| Rodriguez, A | 1 |
| Murray, G | 1 |
| Whyte, S | 1 |
| Norman, JE | 1 |
| Syngelaki, A | 1 |
| Nicolaides, KH | 1 |
| Balani, J | 2 |
| Hyer, S | 2 |
| Akolekar, R | 1 |
| Kotecha, R | 1 |
| Pastides, A | 1 |
| Shehata, H | 2 |
| Sahin, M | 1 |
| Corapcioglu, D | 1 |
| Stanford, FC | 1 |
| Alfaris, N | 1 |
| Misra, M | 1 |
| Ijäs, H | 1 |
| Vääräsmäki, M | 1 |
| Morin-Papunen, L | 1 |
| Keravuo, R | 1 |
| Ebeling, T | 1 |
| Saarela, T | 1 |
| Raudaskoski, T | 1 |
| Gandhi, P | 1 |
| Bustani, R | 1 |
| Madhuvrata, P | 1 |
| Farrell, T | 1 |
| Niromanesh, S | 1 |
| Alavi, A | 1 |
| Sharbaf, FR | 1 |
| Amjadi, N | 1 |
| Moosavi, S | 1 |
| Akbari, S | 1 |
| Glueck, CJ | 1 |
| Goldenberg, N | 1 |
| Pranikoff, J | 1 |
| Khan, Z | 1 |
| Padda, J | 1 |
| Wang, P | 1 |
| Nagai, T | 1 |
| Imamura, M | 1 |
| Mori, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Studies of Metformin and Insulin on Stereological Studies and Immunohistochemistry of Placenta[NCT04907708] | 156 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy[NCT02932475] | Phase 3 | 831 participants (Actual) | Interventional | 2017-05-25 | Terminated (stopped due to Recommendation by the DSMB that the study be stopped for futility) | ||
| Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. A Systematic Review and Meta-analysis of Randomized Controlled Trials Comparing These Drugs Either vs Insulin or vs Each Other.[NCT01998113] | 2,509 participants (Actual) | Observational | 2013-03-31 | Completed | |||
| Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial[NCT06064669] | 988 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women?[NCT01273584] | Phase 2/Phase 3 | 450 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Metformin Versus Insulin in the Treatment of Gestational Diabetes Mellitus: a Randomized Controlled Study[NCT01087866] | Phase 2/Phase 3 | 97 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Metformin Therapy for Gestational Diabetes - Metabolic Late Effects on Child at 9 Years of Age[NCT02417090] | 173 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neonatal fat mass measured by skin-fold thickness (anthropometrics).The circumference of the upper limb is the circumference of the upper arm, and the circumference of the lower limb equals the mean of the circumferences measured at the midthigh and calf. The volume of the subcutaneous layer of fat covering each cylinder is estimated by multiplying the length times the circumference times the layer of fat estimated by the skinfold measures. The triceps skinfold measure is used as an estimate of the fat thickness of the limbs, and the subscapular skinfold measure approximates the fat thickness of the trunk. Total body fat is estimated by summing the volumes of fat covering each of the cylinders and multiplying by 0.9 (the density of fat). (NCT02932475)
Timeframe: Within 72 hrs of birth
| Intervention | kg (Mean) |
|---|---|
| Maternal Metformin | 0.46 |
| Maternal Placebo | 0.5 |
"Participants with one or more of the following:~capillary blood glucose level of < 30 mg/dL or capillary blood glucose requiring medical treatment, or~Birth trauma (umbilical cord artery pH < 7.0 or shoulder dystocia with brachial plexus injury), or~Hyperbilirubinemia requiring phototherapy, or~Deliver < 37 weeks' gestation, or~Miscarry, are stillborn, experience a neonatal demise, or~Large for gestational age infant (birth weight > 90th percentile for gestational age), or~Small for gestational age infant (birth weight < 10th percentile for gestational age) or low birth weight (< 2500 gm)" (NCT02932475)
Timeframe: An average of 48 hours for term infants and 30 days for preterm infants
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin | 269 |
| Placebo | 277 |
Adverse maternal outcomes. (NCT02932475)
Timeframe: An average of 48 hours following delivery
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Any adverse event leading to early study agent discontinuation | Any adverse event associated with maternal death | Any adverse event associated with fetal death | Any maternal serious adverse event | Any maternal non-serious adverse event | |
| Metformin | 13 | 2 | 10 | 113 | 149 |
| Placebo | 20 | 1 | 10 | 111 | 157 |
Adverse neonatal outcomes (NCT02932475)
Timeframe: up to 28 days of life
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any neonatal serious adverse event | Any neonatal non-serious adverse event | |
| Maternal Metformin | 81 | 157 |
| Maternal Placebo | 105 | 162 |
"Secondary outcome of maternal side effects were defined as:~clinically relevant hypoglycemia defined as capillary blood glucose < 60 or < 80 with symptoms~GI side effects defined as nausea, vomiting, diarrhea" (NCT02932475)
Timeframe: Throughout study until delivery at 40 weeks gestation
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Clinically relevant hypoglycemia | Gastrointestinal side effects | |
| Metformin | 87 | 182 |
| Placebo | 85 | 171 |
2 reviews available for metformin and Fetal Macrosomia
| Article | Year |
|---|---|
Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus: An updated PRISMA-compliant network meta-analysis.
Topics: Administration, Oral; Adult; Blood Glucose; Comparative Effectiveness Research; Diabetes, Gestationa | 2017 |
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemi | 2015 |
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemi | 2015 |
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemi | 2015 |
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemi | 2015 |
10 trials available for metformin and Fetal Macrosomia
| Article | Year |
|---|---|
Metformin in gestational diabetes mellitus: A double-blind placebo-controlled randomized trial.
Topics: Blood Glucose; Diabetes, Gestational; Double-Blind Method; Drug Therapy, Combination; Female; Fetal | 2022 |
Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial.
Topics: Adult; Diet Therapy; Double-Blind Method; Exercise; Female; Fetal Macrosomia; Gestational Weight Gai | 2019 |
Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study.
Topics: Adolescent; Adult; Birth Injuries; Diabetes Mellitus, Type 2; Disease Management; Double-Blind Metho | 2018 |
A pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy.
Topics: Adult; Birth Weight; Blood Glucose; Diabetes Mellitus, Type 2; Dystocia; Female; Fetal Macrosomia; G | 2015 |
Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide--a randomised controlled trial.
Topics: Adult; Birth Injuries; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Hum | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial.
Topics: Adult; Birth Weight; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Fetal | 2012 |
Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic | 2013 |
11 other studies available for metformin and Fetal Macrosomia
| Article | Year |
|---|---|
Improving outcomes in gestational diabetes: does gestational weight gain matter?
Topics: Adult; Body Mass Index; Delivery, Obstetric; Diabetes, Gestational; Female; Fetal Macrosomia; Gestat | 2019 |
Longer-term outcomes in offspring of GDM mothers treated with metformin versus insulin.
Topics: Adult; Diabetes, Gestational; Female; Fetal Macrosomia; Follow-Up Studies; Humans; Hypoglycemic Agen | 2018 |
Type 2 diabetes mellitus in pregnancy: The impact of maternal weight and early glycaemic control on outcomes.
Topics: Adult; Case-Control Studies; Cesarean Section; Diabetes Mellitus, Type 2; Female; Fetal Macrosomia; | 2019 |
An Irish National Diabetes in Pregnancy Audit: aiming for best outcomes for women with diabetes.
Topics: Abortion, Spontaneous; Adult; Aspirin; Cesarean Section; Clinical Audit; Delivery of Health Care; De | 2020 |
Exercise vs metformin for gestational diabetes mellitus: Protocol for a network meta-analysis.
Topics: Diabetes, Gestational; Exercise; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Meta-Analysi | 2019 |
Metformin and pregnancy outcomes in obese women.
Topics: Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity, Ab | 2015 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Introduction of metformin for gestational diabetes mellitus in clinical practice: Has it had an impact?
Topics: Adult; Birth Weight; Cohort Studies; Combined Modality Therapy; Diabetes, Gestational; Drug Therapy, | 2012 |
Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Insulin Res | 2003 |